AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05120167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical cell block
Description: Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a cell block and evaluated as histology.
Study NCT05120167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Endocervical curettage
Description: Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
Study NCT05217797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearing glasses (any type)
Description: Participants are asked to wear glasses in public spaces.
Study NCT05263024 — intervention group
Intervention type: DEVICE
Intervention: atrial appendage clip
Description: During cardiac surgery, atrial fibrillation patients were treated with atrial appendage clipping
Study NCT06448234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standart supplementation therapy group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles
Study NCT06448234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-guided supplementation therapy group
Description: Participants receive DS prescriptions determined by an AI system, which considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study NCT06548529 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HER2 expression of PET imaging
Description: Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC
Study NCT06224387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS2190 capsules
Description: 4-6 dose groups are pre-specified in Dose Escalation,and 4 arms in Dose Expansion.
Study NCT05649605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone treatment
Description: Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
Study NCT05649605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Saline solution. Intramuscular injection of physiological saline solution. 4ml administered by trained nurse in the gluteal region at visit 1.
Study NCT05668767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Durvalizumab EP/EC
Description: Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
Study NCT05670808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine injection
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or diagnostic CT
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT or diagnostic CT
Study NCT04541017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV
Study NCT04541017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Given IV
Study NCT04541017 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mogamulizumab
Description: Given IV
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo skin punch biopsy
Study NCT04541017 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Biopsy
Description: Undergo skin punch biopsy
Study NCT05326139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: TA-soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
Study NCT05326139 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Isotonic saline -soaked pledgets were placed under the skin flap in such a way that both sides reach the osteotomy area and left for 5 minutes.
Study NCT05115383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VO2 Max test
Description: The participant will be equipped with a vo2 mask or mouthpiece. They will get on the bike and begin with a 5 minute warmup ranging from 30-100 watts. After the warm up there will be a 15-30 watt increase every minute in the cadence that the participant is required to maintain. Once the participant has decided to stop pedalling, the participants mask will be removed to ensure they are feeling well. They will allowed to continue pedaling at their own pace for a cool down for up to two minutes.
Study NCT05575648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 10 meter walk test
Description: To assess the dual task performance of children 10 meter walk test will be used.
Study NCT05575648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 meter walk test
Description: To assess the dual task performance of children 10 meter walk test will be used.
Study NCT05279521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation exercise
Description: The lung rehabilitation exercise is divided into three parts: upper and lower limb muscle strength, endurance training and breathing training skills. It lasts for eight weeks of exercise training, and the exercise frequency is: three times a week.
Study NCT05315271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-ketamine injection
Description: 20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus ketamine (1 mg/kg) with maximum dose 100mg ; the total volume is 30 ml with the infusion of 100 ml normal saline at a rate of 100ml/h.
Study NCT05315271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine injection with intravenous ketamine infusion
Description: 20 ml volume bupivacaine only (0.5%concentration) (with maximum dose not exceeding 4mg/kg ) plus 10 ml saline ; the total volume is 30 ml with the infusion of ketamine 0.15 mg/kg added to 100 ml normal saline and will be infused at a rate of 100 ml/h, which will be stopped 5 min before the end of surgery.
Study NCT06010394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: ultrasound electrotherapy cold applications
Study NCT06010394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: ultrasound electrotherapy cold applications
Study NCT06010394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises for the knee area
Description: range of motion exercises strengthening exercises exercises to reduce edema
Study NCT06010394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: payment oriented massage
Description: 10 / 15-minute massage treatments to reduce payment
Study NCT05927610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumber Puncture
Description: During the lumbar puncture/LP, 20cc will be collected per standard practice in adult patients. LP will be performed either at bedside or under interventional radiology (IR) guidance (due to patient anatomy).
Study NCT05181007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefanamic Acid
Description: mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
Study NCT05181007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
Study NCT04723433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen gas -Conservative
Description: Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) between 90% and 94%.
Study NCT04723433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen gas -Liberal
Description: Oxygen administration will titrated to a oxyhemoglobin saturation (SpO2) higher than 96%.
Study NCT05670808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epinephrine injection
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Study NCT05355636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fertility Management Counseling
Description: counseling
Study NCT04595487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left ventricular septal pacing
Description: In the LVSP group, instead of placing the standard RV lead, the commercially available 3830 Select Secure (Medtronic, Minneapolis, USA) lead is introduced via standard transvenous approach and positioned against the right ventricular side of the IVS by using the commercially available non-deflectable septal delivery sheath (C315, Medtronic, Minneapolis, USA) under fluoroscopic guidance. Subsequently this pacing lead is advanced/screwed through the interventricular septum until the left ventricular septum is reached. Accurate lead position at the left ventricular septum will be determined anatomically using fluoroscopy, and electrically by evaluating local electrograms and changes in paced electrocardiogram morphology.~In case of unsuccessful lead positioning in the left ventricular septum, the Select Secure lead may be placed at the His bundle region (natural conduction system of the heart) or in the right ventricle according to the physician's discretion.
Study NCT04595487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing
Description: In the RVP group, the ventricular pacing lead is positioned in the right ventricle.
Study NCT05709821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM60
Description: IMM60, every 3 weeks for up to 6 cycles, intravenous (IV) infusion
Study NCT05709821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
Study NCT05709821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, every 3 weeks for up to 35 cycles or approximately 2 years, intravenous (IV) infusion
Study NCT06531863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin is a bioactive compound found in turmeric (Curcuma longa), known for its potent anti-inflammatory, antioxidant, and antimicrobial properties. Its therapeutic effects are primarily attributed to its ability to modulate various molecular targets and signaling pathways within the body
Study NCT06531863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate
Description: Epigallocatechin gallate (EGCG) is a type of catechin, a natural phenol, and antioxidant found predominantly in green tea. EGCG is known for its potent health-promoting properties, including strong antioxidant, anti-inflammatory, and anti-carcinogenic effects.
Study NCT06531863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be consumed after randomization.
Study NCT05957068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Programme
Description: Aerobic exercise consists of 20-minute brisk walks or jogs (5-6 km/h) on the treadmill each session, reaching a heart rate corresponding to 50%-70% of the patient's VO2max (VO2max is determined before embarking on the exercise programme). Study participants are expected to aim for 50% VO2max at the start of the exercise programme, and gradually increasing to 70% VO2max in subsequent exercise sessions. Strength training comprises a series of circuit resistance exercises targeting the major muscle groups. Patients will perform 2-4 sets of these exercises each session, 8-10 repetitions per set. Both aerobic exercise and strength training are done in the same session. With warm-up and cool-down, each session is estimated to take up 1 hour.
Study NCT05957068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care group.
Study NCT06087172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six Minutes Stepper Test (6MST)
Description: Patients were applied two 6MST and 6MWT. 6MWT was conducted to test convergent validity of 6MST.
Study NCT05294107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: additional biopsies
Description: After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.
Study NCT05294107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: additional biopsies
Description: After Verification of eligibility criteria, patient information and consent, digestive biopsies performed for the study are in addition to those performed for the patient's follow-up:~* 6 biopsies are taken on average in clinical routine~* 4 additional biopsies are necessary to obtain a sufficient number of amplifiable stem cells The samples will be sent within one hour to the Biological Resource Center of the University Hospital of Rennes at room temperature in a tube containing isotonic saline. (CRB).~Biopsies will be then prepared by isolating intestinal crypts and cultured on a 3D matrix gel (matrigel) with added growth factors reproducing the niche environment of intestinal stem cells, which favors the development of an intestinal epithelium. After intestinal differentiation, organoids will be used for research such as molecular screening, assessment of the effects of intestinal stress and healing.
Study NCT04460872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Subjects receive testosterone (100 mg/week) by intramuscular injection
Study NCT04460872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Subjects receive locomotor training (4 sessions/week for 2-3 months)
Study NCT04737642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Papillary ballon dilatation
Description: Trans cystic papillary ballon dilatation during cholecystectomy
Study NCT04102475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eatline
Description: After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~* Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition
Study NCT04102475 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: After discharge from the first hospitalization:~* No specific phone calls~* TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~* 6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition
Study NCT04787939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Feeding
Description: Subjects will be permitted to drink liquids by mouth on the first day after surgery. Outcomes related to their care, wound healing, and quality of life will be followed for 30 days after surgery.
Study NCT05475184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-547
Description: Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.
Study NCT05973838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Behavioral Activation (Peer Activate)
Description: The PRS-delivered Peer Activate intervention will consist of approximately six weekly core sessions (approximately 30 minutes-1 hour), and then 6 optional booster sessions to reinforce skill practice. In Peer Activate sessions, participants will learn behavioral activation and problem-solving skills to reduce barriers to medication nonadherence and incorporate value-driven, substance-free, rewarding activities into their daily life to reduce polysubstance use and improve retention.
Study NCT06323642 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic containing Lactobacillus rhamnosus GG.
Description: probiotic containing Lactobacillus rhamnosus GG will be given daily for 3 days
Study NCT06323642 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: milk as placebo
Study NCT06431828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: The patients will download an app through which they will be able to report adverse events related to their cardiovascular health.
Study NCT05035017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Lens
Description: Daily disposable with modified lens design for 2 days
Study NCT05035017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens
Description: Daily disposable with modified lens design for 2 days
Study NCT05035017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Daily disposable lens for 2 days
Study NCT05035017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lens
Description: Daily disposable lens for 2 days
Study NCT04765501 — intervention group
Intervention type: OTHER
Intervention: Survey study
Description: Headache Impact Questionnaire (HIQ) will be applied.
Study NCT04574947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine
Description: Lidocaine IV 1.5 mg / kg BMI will be administered during induction into anaesthesia followed by infusion at a dose of 1.5 mg / kg / h until the end of the surgery.
Study NCT04574947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
Study NCT04574947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
Study NCT04574947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-cuff lidocaine
Description: The lidocaine solution will be applied to the intubation tube and the cuff will be filled with an alkalinised lidocaine solution.
Study NCT04574947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-cuff placebo
Description: The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
Study NCT04574947 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intra-cuff placebo
Description: The intubation tube will be lubricated 0.9% sodium chloride, the tube cuff will be filled with 0.9% sodium chloride solution.
Study NCT06011499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Exercise Intervention
Description: Participate in online supervised, group resistance training sessions (iLIVE)
Study NCT06011499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Diet Intervention
Description: Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)
Study NCT06011499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: Receive usual care receiving educational information about diet and exercise for cancer survivors